Literature DB >> 19666215

The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study.

Lars Helldin1, John M Kane, Fredrik Hjärthag, Torsten Norlander.   

Abstract

INTRODUCTION: This study examines the relationship between having achieved cross-sectional remission and the need for future psychiatric and nursing home care. The study is a prospective long-term follow-up of patients with schizophrenia.
MATERIALS AND METHODS: Cross-sectional remission was defined by applying the Positive and Negative Syndrome Scale (PANSS) criteria requiring that none of the eight core positive and negative symptom items are scored greater than mild. Patients are followed-up by yearly clinical examinations and medical record review. Information on consumption of healthcare resources and residency status were also gathered. Visits to mental health professionals, number and duration of inpatient psychiatric or nursing home admissions were also recorded. The patients are enrolled in a 12 year prospective study, the Clinical Long-term Investigation of Psychosis in Sweden (the CLIPS study). This report covers the first seven years.
RESULTS: Those patients who achieved cross-sectional remission at baseline had a lower total consumption of healthcare services than those who were not in remission. The latter group displayed higher values for all measured variables. DISCUSSION: Our results show that cross-sectional remission is likely to be an important goal to achieve in order to reduce future treatment needs. Patients in remission live a more independent life and have better preconditions for functioning in society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666215     DOI: 10.1016/j.schres.2009.07.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Family burden and functional assessment in the Swedish CLIPS-study: do staff and relatives agree on individuals with psychotic disorders' functional status?

Authors:  Fredrik Hjärthag; Lars Helldin; Anna-Karin Olsson; Torsten Norlander
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-02-25       Impact factor: 4.328

Review 2.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

3.  Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome.

Authors:  Marcelo Valencia; Ana Fresán; Yoram Barak; Francisco Juárez; Raul Escamilla; Ricardo Saracco
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-10       Impact factor: 2.570

4.  Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Authors:  Virginia S Haynes; Baojin Zhu; Virginia L Stauffer; Bruce J Kinon; Michael D Stensland; Lei Xu; Haya Ascher-Svanum
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

5.  Resource Group Assertive Community Treatment (RACT) as a Tool of Empowerment for Clients with Severe Mental Illness: A Meta-Analysis.

Authors:  Tommy Nordén; Ulf Malm; Torsten Norlander
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-16

6.  Involving clients and their relatives and friends in psychiatric care: Case managers' experiences of training in resource group assertive community treatment.

Authors:  Tommy Nordén; Anders Eriksson; Anette Kjellgren; Torsten Norlander
Journal:  Psych J       Date:  2012-06-10

7.  Catching-up: Children with developmental coordination disorder compared to healthy children before and after sensorimotor therapy.

Authors:  Mats Niklasson; Torsten Norlander; Irene Niklasson; Peder Rasmussen
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.